Rectangle Created with Sketch.

About Hoshi

A European focused medical cannabis company.

Hoshi International is a European focused, fully integrated medical cannabis company with strategic assets along the entire value chain including cultivation, processing, and distribution of dry flower and oil derivatives to serve the emerging European market.

Portugal and several countries in the EU including Germany, Italy, Poland, Czech Republic, and the Netherlands have legalized cannabis for medical use and have created frameworks for its distribution and sale. In recent years there has also been a movement in some of the member states, such as Portugal and Germany, to fully legalize cannabis for non-medical adult use. Therefore, the market for cannabis products in Europe, whether it be for medical or legalized adult use, is poised for growth and change, and with a population of 748 million people, Europe is expected to become the largest market for cannabis products in the world. As countries adopt legislation and evolve their regulatory frameworks, demand for products that meet the European quality standard of GMP/GACP is destined to grow rapidly. A lack of domestic infrastructure for this level of product quality has created an opportunity for Hoshi to use its expertise to build and operate a facility that will address the anticipated demand.

Building to supply an evolving market.

Hoshi is one of only a few companies positioned to supply domestically produced, and hence tariff-free cannabis products to this emerging high growth market. Hoshi has been granted a provisional license by INFARMED, I.P., the National Authority of Medicines and Health Products in Portugal and will soon complete construction on a vertically integrated medical cannabis operation in the municipality of Figueiró dos Vinhos, which will allow importing, cultivating, processing, and exporting of cannabis products to EU member states that have legalized cannabis for either medical or non-medical use. Drawing on the experience of its management team in regulated cannabis markets, Hoshi is well positioned to take advantage of the emerging European opportunity.

Our team Contact Us


Hoshi Asset Overview


  • Facility construction nearly complete; expected to be licensed and operational by the end of 2022
  • Producer of high THC GMP flower for the European market
  • Greenhouse cultivation with an option for outdoor cultivation, with over 15 hectares of cultivation area
  • GACP certification expected Q4 2022

Manufacturing & Processing:

  • Facility development plan includes extraction and finished packaging processes
  • Current processing capacity of 12,000 kilograms of dried flower per year
  • GMP certification anticipated in 2023
  • Will be able to provide third party processing services to industry partners with GACP cultivation certification


  • Licensing will include import and export capabilities
  • Distribution of EU-GMP products for legal medical cannabis markets in the EU and the UK
  • Collaborate with distribution partners to find end markets for exported products

Medical Cannabis Pilot Program Under Way

Medical Cannabis Legalization

Medical Cannabis Legalization with Momentum for Recreational Cannabis Legalization

Momentum for Recreational Cannabis Legalization